Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog referenced in endocrine-signaling research literature. This page is maintained as a researcher-facing reference index for nomenclature, source citations, and analytical-verification context only.
Compound Snapshot
- Compound class: GHRH analog
- Sequence length: 44 amino acids
- Modification: N-terminal trans-3-hexenoic acid group
- CAS: 218949-48-5
- Molecular weight: 5135.87 Da
- Primary research theme: GHRH receptor biology and endocrine signaling models
Mechanism Context
In the literature, tesamorelin is discussed as a GHRH receptor agonist. Research interest centers on receptor interaction, endocrine signaling pathways, analytical identity confirmation, and comparison with other GHRH-family compounds.
The N-terminal modification is commonly discussed in relation to enzymatic stability and peptide-chemistry characterization. Those topics belong to compound identification and research design, not consumer guidance.
Published Literature Index
The records below are citations only. They are included for source tracing and literature identification, not as product claims, use guidance, outcome summaries, or recommendations. Researchers should consult the original publications for complete study design, methods, limitations, and safety-review context.
- Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.. DOI:10.1097/QAI.0b013e3181cbdaff. PubMed PMID: 20101189
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.. DOI:10.1210/jc.2010-0490. PubMed PMID: 20554713
- Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Bhatt RS, Grinspoon SK.. DOI:10.1093/cid/cis251. PubMed PMID: 22495074
- Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK.. DOI:10.1001/jama.2014.8334. PubMed PMID: 25038357
- Scherzinger A, Sanyal A, Lake JE, Falutz J, Dube MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM.. DOI:10.14283/jfa.2018.45. PubMed PMID: 31237318
- Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg DL, Branch K, Lee H, Torriani M, Corey KE, Chung RT, Grinspoon SK.. DOI:10.1016/S2352-3018(19)30338-8. PubMed PMID: 31611038
Analytical Verification Context
Research-grade tesamorelin should be evaluated through identity and purity documentation such as HPLC and mass-spectrometry records. Batch-specific COA review, lot traceability, and independent laboratory verification are the relevant quality-control checks for this compound class.
For Chameleon Peptides materials, batch-specific identity, purity, and applicable endotoxin documentation is maintained on the public COA & Batch Verification Ledger. Those records should be read as analytical documentation for research reagents only, not as medical-use, diagnostic, treatment, or preparation guidance.
This article is for educational and informational reference only. Chameleon Peptides supplies research materials for qualified laboratory investigation. The information here is not clinical guidance, not a recommendation for any application, and not instructions for preparation or application.